Contact Information: CONTACT: Debra Bannister 530 676-8001
REGiMMUNE Receives Grant Award From METI
| Source: REGiMMUNE
MOUNTAIN VIEW, CA and TOKYO, JAPAN--(Marketwire - August 8, 2007) - REGiMMUNE Corporation, a
privately held biopharmaceutical company, announced today it has been
awarded a grant from the Japanese Ministry of Economy, Trade and Industry
(METI). REGiMMUNE received the grant under the METI-sponsored Regional New
Consortium Projects/New Industry Creative-Type Technology R&D Promotion
Programs, which is intended to promote new industries and new small
businesses in Japan.
The one-time grant will provide a portion of the funds for the company's
development of its immune regulatory therapeutics for cedar allergy. The
METI program is similar to the Small Business Innovation (SBIR) grant
programs from U.S. government agencies such as the National Institutes of
Health and the Centers for Disease Control.
"This award validates the importance of REGiMMUNE's reVax technology to
address the unmet need for cedar allergy treatments, which is an urgent
issue in Japan," said Haru Morita, President and Chief Executive Officer of
REGiMMUNE. "We are pleased that METI has recognized the potential of our
technology with this generous grant."
About REGiMMUNE
REGiMMUNE is a biotechnology company focused on the discovery, development
and commercialization of immune regulatory therapeutics to treat
life-threatening and debilitating conditions, including allergies,
autoimmune diseases and inflammatory disorders. The company's proprietary
technology platform, reVax (reverse vaccination), works by modulating the
immune system by enhancing antigen specific immune regulatory cells. This
technique is expected to be useful in conditions such as Ragweed Allergy,
Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an
abnormal immune response is desirable. reVax is being utilized to advance
several compounds through clinical development and eventual
commercialization of a broad range of products for REGiMMUNE and its
partners. The company is headquartered in Tokyo, Japan and has a U.S.
subsidiary in Mountain View, California. For more information, please
visit www.regimmune.com.